THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Beren Therapeutics P.B.C., a leader in cholesterol-trafficking biology and novel cyclodextrin-based therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved LEMBAZ™ (adrabetadex), the first medicine to address the underlying cholesterol trafficking defect that causes Niemann-Pick disease, type C (NPC) and the first medicine to improve survival in infantile-onset NPC (I-NPC). LEMBAZ is approved for adults and children wit